Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303134 · ClinicalTrials.gov registry record · Phase 1
Islet Cell Transplants for Diabetes
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00303134 is a Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 3 participants.
The verdict
NCT00303134, a Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of islet cell transplants for the treatment of type 1 diabetes mellitus. It has been shown that normal control of blood sugar levels can prevent progression of complications (such as kidney disease, nerve damage, and vascular disease) from diabetes. This research study is designed to see if normal blood sugar control can be achieved by transplanting pancreatic islet cells into your liver, which may reduce or eliminate your need for insulin. Patients may qualify to participate in this research study if they have type 1 diabetes mellitus for at least five years and meet at least one of the following criteria: * Experience hypoglycemic unawareness - Defined as inability to tell when blood glucose is low (for example, may not feel symptoms such as shaking, sweating, and rapid heartbeat that usually signify that glucose is low) * Have been hospitalized several times in the past year for low blood sugar and/or high blood sugar * Have complications of diabetes such as retinopathy, kidney problems, or neuropathy
Interventions
- DRUG Islet Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2003-08-01 |
| Est. Completion | 2010-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303134
The ClinicalTrials.gov registry entry for NCT00303134 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Islet Cell Transplantation is the first listed.
NCT00303134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303134 about?
NCT00303134 is a clinical study titled "Islet Cell Transplants for Diabetes". The purpose of this study is to test the safety and efficacy of islet cell transplants for the treatment of type 1 diabetes mellitus. It has been shown that normal control of blood sugar levels can prevent progression of complications (such as kidney disease, nerve damage, and vascular disease) from...
What is the current status of trial NCT00303134?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2003-08-01. Estimated completion is 2010-06-24.
What interventions are being tested in trial NCT00303134?
The interventions under investigation include: Islet Cell Transplantation (DRUG).
Who is sponsoring clinical trial NCT00303134?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.